Background: Treatment of HCV/HIV coinfection is now largely based on utilization of direct acting agents. Pretreatment viral resistant-associated variants (RAVs) and host liver condition may affect the sustained virological response. In this study, we explored relative prevalence of protease resistance-associated mutations, the evolution of those RAVs after 12 weeks of pegylated interferon alfa exposure, and the role hepatic fibrosis might have on RAV display.
INTRODUCTION
Approximately 25% of persons infected with HIV are coinfected with hepatitis C virus in the United States. 1 HCV/HIV coinfection is associated with an increased risk of liver fibrosis, cirrhosis and more rapid progression to end-stage liver disease compared with those with either HCV or HIV monoinfection. [2] [3] [4] [5] [6] [7] Treatment of HCV/HIV coinfection is now largely based on utilization of direct acting agents, whose action targets the nonstructural protein (NS) 3/4, a serine protease, the NS5A domain, a pleiotropic phosphoprotein and/or in the NS5B, an RNA-dependent RNA polymerase. Variation in key binding sites in each of these regions leads to drug resistance. 8 In this study, we explored (1) the distribution and relative prevalence of resistance-associated variants (RAVs) associated with protease inhibitor resistance discovered using ultra-deep sequencing methods, (2) the evolution of these RAVs after long-term exposure to pegylated interferon (PegIFN) alfa, and (3) the effect hepatic fibrosis, determined by sensitive computer-assisted histomorphometry, has on RAVs display.
SUBJECTS AND METHODS
Thirty HCV/HIV-coinfected subjects were evaluated. All subjects were previously enrolled/consented in ACTG 5178 (SLAM-C), a study designed to evaluate the effects of prolonged PegIFN on hepatic fibrosis (ClinicalTrials.gov Identifier: NCT00078403). A detailed description of the study design and subject enrollment criteria is described and published elsewhere. 9 The 30 subjects included in this part of the study had failed to achieve an early viral response (,2 log drop in viral load) after 12 weeks of PegIFN/ ribavirin treatment.
Ethical Approvals and Consent for Participation
This clinical study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. The patients' consent and protocol of the study were approved by the University of Cincinnati Institutional Review Board. An independent Safety Monitoring Committee (SMC) provided oversight during the conduct of the trial.
Description of HCV Amplicon-Seq
The amplicon-seq targeting HCV genome variable region was performed by the Genomics, Epigenomics and Sequencing Core (GESC) in the University of Cincinnati. Reverse transcription polymerase chain reaction (RT-PCR) HCV NS3-specific primers were used to amplify a partial sequence of the HCV NS3. The SuperScript III one-step RT-PCR Platinum Taq HiFi (Invitrogen, Carlsbad, CA) was used to amplify all samples according to the manufacturer's recommendations. RT-PCR-amplified product (600 bp) was agarose gel-purified with the final sample volume adjusted to 100 mL. Nanodrop results showed that the concentrations of the purified DNA ranged from a few to 30 ng/mL, which is suitable for the DNA library preparation.
To shear the DNA to proper size range for library preparation, 50 mL of DNA was aliquoted to a microTUBE (Covaris, Woburn, MA) and sonicated with Covaris S2 focused-ultrasonicator under the protocol targeting 150 bp peak. The sheared DNA was analyzed for quality control using Bioanalyzer DNA 1000 chip (Agilent, Santa Clara, CA).
Automatic DNA-Seq Library Preparation
PrepX DNA Library kit (WaferGen, Fremont, CA) and Apollo 324 NGS automatic library prep system (WaferGen) were used for the library preparation. ChIP-seq script was selected to capture all the sheared fragments that were over ;80 bp. First, the sheared DNA fragments with overhangs were converted into blunt ends in the end repair procedure and adenylated at 39 ends for TA ligation to Illumina (San Diego, CA) sequencing adaptors. Next, the ligated library was enriched by 6 cycles' of PCR using index-specific primers, followed by AMPure XP beads (Beckman Coulter, Brea, CA) purification. A Bioanalyzer DNA high-sensitivity chip was then used to check the quality and yield of the purified library. To accurately quantify the library concentration for the clustering, the library was 1:10,000 diluted in dilution buffer (10 mM Tris-HCl, pH 8.0 with 0.05% Tween 20) , and quantitative PCR analyzed using Kapa Library Quantification kit (Kapa Biosystem, Woburn, MA) using ABI's 9700HT real-time PCR system (Lifetech, Grand Island, NY).
Cluster Generation and HiSeq Sequencing
Individually indexed libraries were proportionally pooled for clustering at a final concentration of 8 pM. The pooled libraries were clustered onto a flow cell using Illumina's TruSeq SR Cluster kit v3 in cBot system (Illumina), followed by single read sequencing at 1 · 50 bp using Illumina's TruSeq SBS kit on HiSeq system (Illumina). Approximately 3 million reads were generated from each sample for data analysis. RAVs were detected down to a proportional frequency of ,1%.
Liver Morphometric Analysis
HCV RNA from week 12 was used to determine response status. During this period, a liver biopsy was performed if the subject was classified as a treatment nonresponder. Liver biopsies from step 2 entry were transferred to a central site where they were deidentified and coded. Biopsies were then shipped to the central pathologist (Z.D.G.) where they were evaluated in a blinded manner by 2 independent reviewers, using the Metavir and Ishak scoring criteria. In addition to standard microscopy, we used computer-generated assessment of liver tissue. 10 Sections of liver tissue were stained with picrosirius red for assessment of collagen. A digitized image of each section, including all tissue in the section, was acquired using an Aperio XT slide scanner at ·20 magnification. The Aperio positive pixel count algorithm was used to identify and classify each red pixel (hue 0.95 6 0.1) in the picrosirius red-stained section as collagen. Each red pixel was compared with the total percentage of pixels in the sample (Fig. 1) . Accuracy of classification was confirmed by visual inspection of the appearance under the microscope relative to the computer-generated reading. Samples with poor stain uptake were restained or eliminated from the result. Results were expressed as a fraction of tissue positive for collagen.
Bioinformatics and Statistical Analysis
The filtered, trimmed sequencing reads were aligned to the H77C reference sequence, HCV genotype 1, from the Los Alamos HCV database (http://www.hcv.lanl.gov). The codons associated with RAVs were identified, and the mutation frequency was calculated. The mean coverage was 372,324, and the threshold for variant frequency was 0.3% of the total population sample. Sequencing reads were processed according to the following standards: an exact match to primer sequences; no ambiguous bases; sequence base calls with Illumina low-error rates quality scores.
Age, race, sex, HCV genotype, HIV RNA, HCV RNA, alanine aminotransferase, aspartate aminotransferase, platelet count, and bilirubin measures were collected. Frequency distribution of data was measured. Summary of mean 6 SD is presented. Spearman r was used to measure correlation between parameters. For all comparisons, 2-sided P values, 0.05, were considered statistically significant.
RESULTS

Demographics and Clinical Characteristics
The study cohort was predominantly men (83.3%), with a median age of 47 years. Forty percent were white and 56.7% black. Baseline mean HCV log 10 viral load was 6.6 IU/mL and HIV viral load was 3365.1 copies/mL. Because of effective Combination antiretroviral therapy (cART), 56.7% had undetectable HIV. IL28B distribution for C/C, C/T, and T/T were 35, 45, and 20%, respectively. Sixteen patients were genotype 1a, 2 were 1a1b, and 12 were type 1 no subtype (Table 1) .
Frequency and Evolution of HCV NS3 Variants
At baseline, protease-coding domain RAVs were present in 22/30 patients (73.3%) and extended to 25/30 patients (83.3%) after 12 weeks. At baseline, V36M/L, T54A/S, V55I, and D168G were each detected in 3.3% of patients. V55A was detected in 6.7% of patients. I170V was present in 36.7% of patients. Q80K showed the highest prevalence at 46.7% (Fig. 2) . Evolution of these protease RAVs after 12 weeks of treatment showed that V36M and V55I expanded to 6.7% and 10% of the population, respectively, while Q80K was selected in 56.7%. The proportion of subjects having detectable V55A and I170V declined to 3.3% and 23.3% of patients, respectively. Over all amino acid positions studied, no statistical difference in relative abundance of RAVs within a patient before and after 12 weeks of treatment was seen. There was no relationship with IL28B, viral loads, age, sex, or race.
Liver Morphometric Analysis
Liver biopsy was obtained from enrolled nonresponder patients after 12 weeks of treatment. Computerassisted assessment of liver tissue was determined. The mean 6 SD of the liver biopsy length, area, and percent collagen content in the studied patients were 21.913 6 9.74 mm, 13.648 6 8.61 mm 2 , and 10.913 6 7.05, FIGURE 1. Liver biopsy analyzed for collagen by computerassisted morphometry. Image on the left is the biopsy stained with picrosirius red. Collagen is red and noncollagen is yellow. Image on the right is the same biopsy after morphometric analysis. Collagen is represented by red pixels, whereas noncollagen pixels are colored blue. Red pixels, which are the area of collagen, are 19.5% of the total. (20) respectively. The percent collagen content of the liver after 12 weeks of treatment showed a statistically significant correlation with the frequency of Q80K (r = 0.6160, P = 0.0145) in treatment nonresponding patients with HCV/ HIV (Fig. 3) .
DISCUSSION
Naturally occurring resistance-associated variances are important factors in several all-oral therapeutic regimens in HCV and HCV/HIV-coinfected populations. In this study, we determined the baseline representation of HCV protease inhibitor RAVs in 30 HCV/HIV-coinfected patients using a highly sensitive deep sequencing technique. We further explored changes in these populations over time when nonspecific therapy (PegIFN) is applied.
The HCV virus explores virtually all possible combinations of a sequence on a daily basis. 11 While most result in nonreplicative virus, minor variations may result in relative resistance to antiviral therapy with virtual preservation of viral fitness. These resistant mutations may emerge during exposure to and pressure from extrinsic antiviral agents leading to overt viral resistance. 12, 13 At baseline, the vast majority of patients harbor HCV protease RAVs. The proportion of RAVs that exist at baseline may represent an important predictor of emergence. Lok et al noted that R155K mutations present at baseline were associated with development of viral relapse after a course of treatment with a combination of daclatasvir (NS5A inhibitor) and the protease inhibitor (PI) asunaprevir. 14 This emergence was prevented if PegIFN and ribavirin were part of a quad therapy regimen. These observations suggest that the importance of minor variants may increase, as PegIFN is no longer part of the treatment regimen. The high-level RAV, R155, was not detected in the HCV/HIVtested population either before or after 12 weeks of PegIFN. Only a few studies have looked at natural variability of NS3 in the HCV/HIV-coinfected patients using highly sensitive deep sequencing techniques. [15] [16] [17] [18] The results of these studies showed a higher natural prevalence of protease resistance variance in the coinfected population as compared with that of HCV monoinfection. In this study, we further considered the evolution of the protease variants after 12 weeks of non-directly acting antiviral (DAA) treatment. After 12 weeks of treatment, V55I and V36M expanded to 9% and 12% of the population, respectively. The Q80K variant was present at baseline in 46.7% of the population but was detected in approximately 56.7% of HCV/HIV-coinfected patients after PegIFN exposure. The continued viral replication after 12 weeks of PegIFN may have put the patients at risk of developing or selecting for drug resistance viruses with high replicative capacities. 19 This implies that pressure from nontargeted therapies could lead to selection. In HCV-monoinfected patients; wide variation in Q80K representation is reported. In a European study, Q80K was present among HCV genotypes 1, 1a, and 1b at rates of 7.5%, 19.8%, and 0.5%, respectively. 18 The prevalence of the Q80K variant is higher in the United States scaling to 47% in genotype 1a. 20 Among the 2 identified clades of HCV subtype 1a, Q80K associates strongly with clade 1 21 and is thought to have originated in the United States during the 1940s. 22 The Q80K polymorphism has been shown to substantially reduce the efficacy of simeprevir, a Food and Drug Administration-approved protease inhibitor indicated for use with PegIFN/ribavirin. 23 Thus, baseline Q80K screening is recommended before simeprevir treatment. 24 This study reports a natural prevalence of Q80K in 14 (46.7%) of 30 HCV/HIV-coinfected patients. Previous studies, that used comparable HCV NS3-deep sequencing techniques, reported similar Q80K high frequency in 17 (42.5%) of 40, 15 and in 12 (57.1%) of 21 of HIV/HCV-coinfected patients, respectively. 16 The high proportion of Q80K observed in U.S. patients with HCV/HIV coinfection suggests that the choice of therapeutic agents should be tailored to this finding. A limitation of this study is that controls with HCV or HIV monoinfection were not available in the particular cohort described in this study for comparison.
Liver biopsies were obtained from enrolled patients with HCV/HIV who did not show an early response after 12 weeks of nontargeted therapy. We found a significant correlation between the percentage of hepatic collagen content and the expanded Q80K frequency after 12 weeks of treatment but not with the Q80K variant frequency at baseline. In a proposed model by Talal et al, it was suggested that there are high-and low-level sites of HCV replication within the liver. This suggests that most plasma HCV RNA may have originated from the higher level replication foci within the infected liver before treatment. Early viral response to treatment may be a result of inhibition of those major replication foci. The advance in hepatic fibrosis can affect those higher HCV-replicating sites with consequently lower decline rates in HCV viral load and intrahepatic drug concentration. This might affect interferon-induced clearance of the infected cells from the liver. 25 This could explain the positive correlation between liver collagen content and the evolution of the HCV NS3 Q80K variant after treatment in our coinfected population. The distortion of the liver compartment with more collagen deposition and fibrosis progression might have led to lower blood flow to protected areas in the liver and thus to suboptimal concentration of the drug, higher viral replication rate within the liver, and emergence of variants such as HCV NS3 Q80K. We think that the effect of compartmentalization induced by the presence of cirrhosis is independent of the initial treatment in this cohort. However, different anti-HCV agents might have a differential effect on selection because of variable penetrance into protected fibrotic compartments. This will have to be explored further in ongoing studies.
In summary, this study is one of few that explored natural resistance protease variance in patients with HCV/ HIV using next generation sequencing. Key RAVs for HCV protease inhibitors are present in a large portion of the HCV/HIV-coinfected population before therapy. The prevalence of V36M, V55I, and Q80K seems to be increased after prolonged therapy with PegIFN and ribavirin, suggesting that pressure from nontargeted therapies could lead to selection. Correlation of Q80K frequency with collagen content of the liver after 12 weeks of nontargeted therapy suggests the possibility that compartmentalization within the liver may contribute to persistence of mutations less fit than wildtype.
